AKASA vs RapidClaims
Two Autonomous Medical Coding vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| AKASA | RapidClaims | |
|---|---|---|
| Pricing model | Enterprise contract (custom) · Subscription sized by transaction volume | Not published |
| Speed to go live | 60-90 days typical; longer multi-facility | Claims six weeks to production via API |
| Automation model | Autonomous agents · GenAI automation with human review | Autonomous agents · Human review on low-confidence charts |
| Built for | Mid-size groups, Enterprise systems | Mid-size groups, Enterprise systems, Billing companies |
| Security posture | HITRUST, SOC 2 Type II, HIPAA | SOC 2 Type II, HITRUST, HIPAA |
| Company maturity | 8 yrs (est. 2018) | 3 yrs (est. 2023) |
| Financial backing | $205M · Series B | $11M · Series A |
| Named customers | 2 named | None public |
| Published results | Specific numbers public | Specific numbers public |
| Documented integrations | 3 listed | 5 listed |
| Third-party validation | None found | None found |
Bottom line
- Pick AKASA if you run a mid-size or large health system, ideally on Epic, and want generative AI working claims, auths, and coding in-house instead of outsourcing staff.
- Pick RapidClaims if you want one AI platform spanning coding, scrubbing, and denials rather than a standalone coding engine.
AKASA
Generative AI for coding and revenue cycle operations
- Founded
- 2018
- HQ
- South San Francisco, CA
- Stage
- Series B
- Raised
- $205M
What it does
- Generative AI medical coding trained on clinical documentation
- Clinical documentation integrity (CDI) review at scale
- Automates prior auth status and claims follow-up work
- LLMs fine-tuned on customer clinical and financial data
- Surfaces missed codes and documentation gaps pre-bill
Where it's strong
- Cleveland Clinic co-developed and is now deploying its GenAI CDI product across all US locations, a rare tier-one clinical validation.
- Deep pockets ($205M raised) and deployment across 650+ hospitals reduce vendor-viability risk.
- Focus on mid-revenue-cycle (coding plus CDI) fits health systems that want one vendor for both.
What buyers should weigh
- The company pivoted from RPA-style automation to generative AI, so ask which product generation you are actually buying.
- Flagship proof points are large academic systems; fit and pricing for smaller hospitals is less proven.
- Last disclosed raise was 2022, so probe current burn and roadmap funding.
Named customers
Cleveland Clinic · Duke University Health System
Integrations
RapidClaims
Autonomous AI coding and claim scrubbing across the revenue cycle
- Founded
- 2023
- HQ
- New York, NY
- Stage
- Series A
- Raised
- $11M
What it does
- Autonomous coding across 20+ specialties (RapidCode)
- Pre-bill claim scrubbing and edits
- Clinical documentation improvement prompts
- Denial management and appeals (RapidRecovery)
- AR follow-up within one workflow
- Audit trails for every coded chart
Where it's strong
- Covers documentation through denial appeal in one platform, so you avoid stitching point tools.
- Claims 98% coding accuracy with production deployment in about six weeks.
- Reference results include a 30% A/R day reduction and 40% lower coding cost.
What buyers should weigh
- No customers are publicly named, so reference checks require NDA conversations.
- At $11M raised it is earlier-stage than incumbent coding vendors.
- Accuracy claims are self-reported; validate on your own specialty mix in a pilot.
Integrations
Compare against the rest of Autonomous Medical Coding
Deciding between these two?
First Pass tracks Autonomous Medical Coding every week: funding, launches, and what changed since this page was written.